The annual meeting of doctors who treat blood disorders like leukemia and sickle cell is under way. Scientific breakthroughs have made hematology an exciting focus for patients and investors these days, and Saturday’s start of the American Society of Hematology’s yearly conference features encouraging news from developers of cancer-fighting antibodies, cell therapies, and genetic medicines.
Some of the most-anticipated results at the Atlanta meeting are coming from bluebird bio (ticker: BLUE). The company’s gene therapies…